Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Macozinone - Ecole Polytechnique Federale de Lausanne/Nearmedic

Drug Profile

Macozinone - Ecole Polytechnique Federale de Lausanne/Nearmedic

Alternative Names: PBTZ-169; PBTZ169 NCP

Latest Information Update: 07 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator A. N. Bach Institute of Biochemistry; Ecole Polytechnique Federale de Lausanne.
  • Developer NEARMEDIC
  • Class Antituberculars; Cyclohexanes; Fluorinated hydrocarbons; Nitrobenzenes; Piperazines; Thiazines
  • Mechanism of Action Cell wall inhibitors; DprE1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Tuberculosis

Most Recent Events

  • 12 Sep 2019 Chemical structure information added
  • 31 Dec 2018 Innovative Medicines for Tuberculosis plans a phase Ib trial for (In volunteers) in Switzerland (PO) (NCT03776500)
  • 22 Feb 2018 Nearmedic terminates a phase II trial in Tuberculosis due to slow enrolment (PO) (NCT03334734)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top